Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Chihiro Morishima"'
Autor:
Andreanne M. Lacroix, Steven P. Fling, Lawrence Fong, Chihiro Morishima, Frederick Millard, Nirasha Ramchurren, Russell K. Pachynski, Martin A. Cheever, Anne Gregoire, Lauren C. Harshman, Paul Monk, Omer Kucuk, Leonard A D'Amico, Leonard Joseph Appleman, Michel Morre, John D. Seigne, Caroline Duault, Judith C Kaiser, Russell Z. Szmulewitz, Evan Y. Yu, Bruce W. Hess, Rhonda L. Bitting, Holden T. Maecker
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for immunotherapy of cancer, vol 9, iss 8
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 8
Journal for Immunotherapy of Cancer
BackgroundSipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic
Autor:
Jack O. Egan, Jeffrey S. Miller, Ann W. Silk, Martin A. Cheever, Hing C. Wong, Sylvia Lee, Steven P. Fling, Peter R. Rhode, Chihiro Morishima, Shernan G. Holtan, Andreanne M. Lacroix, Kim Margolin, Judith C Kaiser, Monica Brown Jones, Marc S. Ernstoff, Amy Rock, Vamsidhar Velcheti
Publikováno v:
Clinical Cancer Research. 24:5552-5561
Purpose: IL15 induces the activation and proliferation of natural killer (NK) and memory CD8+ T cells and has preclinical antitumor activity. Given the superior activity and favorable kinetics of ALT-803 (IL15N72D:IL15RαSu/IgG1 Fc complex) over reco
Autor:
Judith C Kaiser, Douglas G. McNeel, Howard Streicher, Manish R. Patel, Holbrook E Kohrt, Mary L. Disis, Martin A. Cheever, Steven P. Creekmore, Jeffrey S. Miller, Heather A. Wakelee, Chihiro Morishima, Paul M. Sondel, Kevin C. Conlon, Thomas A. Waldmann, John A. Thompson
Publikováno v:
Clinical Cancer Research. 24:1525-1535
Purpose: Preclinical data established IL15 as a homeostatic factor and powerful stimulator of NK and CD8+ T-cell function, the basis for clinical testing.Experimental Design: A first-in-human outpatient phase I dose escalation trial of subcutaneous (
Autor:
Chihiro Morishima, Gyongyi Szabo, Jules L. Dienstag, Deepa Naishadham, Elizabeth C. Wright, Anna S.F. Lok, Adrian M. Di Bisceglie, Marc G. Ghany, Karen L. Lindsay, Gregory T. Everson, Mitchell L. Shiffman, Timothy R. Morgan
Publikováno v:
American Journal of Gastroenterology. 107:1388-1398
During the Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial, 3.5 years of maintenance peginterferon-alfa-2a therapy did not affect liver fibrosis progression or clinical outcomes among 1,050 previous interferon nonresponders with adv
Autor:
Marc G. Ghany, William M. Lee, Jules L. Dienstag, Elizabeth C. Wright, Anna S.F. Lok, Gregory T. Everson, Herbert L. Bonkovsky, Mitchell L. Shiffman, Chihiro Morishima, Karen L. Lindsay, Timothy R. Morgan
Publikováno v:
Clinical Gastroenterology and Hepatology. 6:234-241
Background & Aims: Peginterferon with ribavirin therapy for chronic hepatitis C leads to sustained loss of serum hepatitis C virus (HCV) RNA in half of treated patients. Although viral kinetic profiles in treatment responders shed light on the mechan
Autor:
Adrian M. Di Bisceglie, David R. Gretch, Timothy R. Morgan, Herbert L. Bonkovsky, Jules L. Dienstag, Karen L. Lindsay, Mitchell L. Shiffman, Anna S.F. Lok, Marc G. Ghany, William M. Lee, Elizabeth C. Wright, Chihiro Morishima, James E. Everhart, Gregory T. Everson
Publikováno v:
Hepatology. 44:360-367
For making treatment decisions related to chronic hepatitis C, the utility of HCV RNA tests with increased sensitivity has not been defined. Prior interferon nonresponders with advanced fibrosis (n = 1,145) were retreated with peginterferon alpha-2a
Autor:
Kersten Gaba, David R. Gretch, Robert L. Carithers, M. Juliana McElrath, Chihiro Morishima, Megan Allison, Luwy Musey, Marnie Elizaga
Publikováno v:
Clinical Immunology. 108:211-220
Antigen-specific T cells are likely to provide a critical defense against hepatitis C virus (HCV) infection. However, their detection in blood is uncommon except in persons who undergo spontaneous recovery after acute HCV infection. We postulated tha
Autor:
Jules L. Dienstag, Elizabeth C. Wright, Timothy R. Morgan, Chihiro Morishima, William M. Lee, Herbert L. Bonkovsky, Anne M. Stoddard, Leonard B. Seeff, Marc G. Ghany, Kristin K. Snow, Adrian M. Di Bisceglie, Mitchell L. Shiffman, Robert J. Fontana
Chronic hepatitis C virus infection can cause chronic liver disease, cirrhosis and liver cancer. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial was a prospective, randomized controlled study of long-term, low-dose pegi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cc78cd26359500b7baa56e03c30b976
https://europepmc.org/articles/PMC3073857/
https://europepmc.org/articles/PMC3073857/
Autor:
Herbert L. Bonkovsky, Deepa Naishadham, Chihiro Morishima, Timothy R. Morgan, Richard W. Lambrecht, Thomas E. Rogers, Richard K. Sterling, Anne M. Stoddard
Publikováno v:
Gastroenterology. 140(5)
Iron may influence severity and progression of non-hemochromatotic liver diseases. Our aim was to assess the relationship of iron and HFE genetic variations to progression and outcomes in the HALT-C Trial and whether PegIFN therapy influenced iron va
Autor:
Richard K. Sterling, Gregory T. Everson, Elizabeth C. Wright, Adrian M. Di Bisceglie, Marc G. Ghany, Herbert L. Bonkovsky, James E. Everhart, Chihiro Morishima, Jules L. Dienstag, William M. Lee, Karen L. Lindsay, Timothy R. Morgan, Hae-Young Kim, Anna S. Lok
Publikováno v:
Gastroenterology. 140(3)
Background & Aims Interferon reportedly decreases the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial showed that 4 years of maintenance